LON:CIR - Circassia Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 32.28 -0.02 (-0.06 %) (As of 03/26/2019 04:00 PM ET)Previous CloseGBX 32.30Today's RangeGBX 31.75 - GBX 33.2052-Week RangeGBX 31.90 - GBX 98.30Volume45,648 shsAverage VolumeN/AMarket Capitalization£120.79 millionP/E Ratio-1.22Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartInsider TradesHeadlinesOptions Chain Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Circassia Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of respiratory diseases. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; and Tudorza for the treatment of chronic obstructive pulmonary disease (COPD). Its pipeline products include Flixotide, Seretide, and Flovent for asthma; and various novel specialty for COPD treatments, such as Duaklir, Spiriva, Novel LABA/LAMA formulation, and novel COPD therapy formulation. The company has a collaboration agreement with AstraZeneca to promote Tudorza and for COPD treatment, and has the United States commercial rights to COPD therapy Duaklir. It markets its products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners in China, Japan, Europe, and internationally. Circassia Pharmaceuticals plc was founded in 2006 and is headquartered in Oxford, the United Kingdom. Receive CIR News and Ratings via Email Sign-up to receive the latest news and ratings for CIR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:CIR Previous Symbol CUSIPN/A CIKN/A Webwww.circassia.co.uk Phone44 1865 405 560Debt Debt-to-Equity RatioN/A Current Ratio2.81 Quick Ratio2.64Price-To-Earnings Trailing P/E Ratio-1.22 Forward P/E Ratio-6.32 P/E GrowthN/A Sales & Book Value Annual Sales£56.40 million Price / Sales2.14 Cash FlowGBX 15.19 per share Price / Cash Flow2.13 Book ValueGBX 59.40 per share Price / Book0.54Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares374,251,008Market Cap£120.79 million Next Earnings Date4/24/2019 (Estimated) OptionableOptionable Circassia Pharmaceuticals (LON:CIR) Frequently Asked Questions What is Circassia Pharmaceuticals' stock symbol? Circassia Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "CIR." When is Circassia Pharmaceuticals' next earnings date? Circassia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, April 24th 2019. View Earnings Estimates for Circassia Pharmaceuticals. What price target have analysts set for CIR? 4 analysts have issued twelve-month price objectives for Circassia Pharmaceuticals' shares. Their predictions range from GBX 65 to GBX 140. On average, they expect Circassia Pharmaceuticals' share price to reach GBX 98.75 in the next twelve months. This suggests a possible upside of 206.0% from the stock's current price. View Analyst Price Targets for Circassia Pharmaceuticals. What is the consensus analysts' recommendation for Circassia Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Circassia Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Circassia Pharmaceuticals. Has Circassia Pharmaceuticals been receiving favorable news coverage? News coverage about CIR stock has trended negative this week, InfoTrie reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Circassia Pharmaceuticals earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near term. Who are some of Circassia Pharmaceuticals' key competitors? Some companies that are related to Circassia Pharmaceuticals include Biotest (BIO), Polynovo (PNV), Oxford BioMedica (OXB), Senesco Technologies (ELOX), Starpharma (SPL), Neptune Wellness Solutions (NEPT), Enochian Biosciences (ENOB), Emblem (EMC), Monash IVF Group (MVF), IMV (IMV), BELLUS Health (BLU), Horizon Discovery Group (HZD), Kodiak Sciences (KOD), 22nd Century Group (XXII) and BioTime (BTX). What other stocks do shareholders of Circassia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Circassia Pharmaceuticals investors own include ABZENA/PAR VTG FPD 0.002 (ABZA), Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Oxford BioMedica (OXB), Livexlive Media (LIVX), Aquantia (AQ), Cohbar (CWBR), Clearside Biomedical (CLSD), Mirati Therapeutics (MRTX) and Ampio Pharmaceuticals (AMPE). Who are Circassia Pharmaceuticals' key executives? Circassia Pharmaceuticals' management team includes the folowing people: Mr. Steven Charles Andrew Harris, Co-Founder, CEO & Director (Age 52)Mr. Julien Cotta, CFO, Company Sec. & Director (Age 55)Dr. Roderick Peter Hafner, Sr. VP of R&D and Director (Age 53)Ms. Nina Kataria, Sr. VP Global HRDr. Kathleen Rickard, Head of Clinical Devel. (Age 61) How do I buy shares of Circassia Pharmaceuticals? Shares of CIR and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Circassia Pharmaceuticals' stock price today? One share of CIR stock can currently be purchased for approximately GBX 32.28. How big of a company is Circassia Pharmaceuticals? Circassia Pharmaceuticals has a market capitalization of £120.79 million and generates £56.40 million in revenue each year. What is Circassia Pharmaceuticals' official website? The official website for Circassia Pharmaceuticals is http://www.circassia.co.uk. How can I contact Circassia Pharmaceuticals? The company can be reached via phone at 44 1865 405 560. MarketBeat Community Rating for Circassia Pharmaceuticals (LON CIR)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 37 (Vote Outperform)Underperform Votes: 37 (Vote Underperform)Total Votes: 74MarketBeat's community ratings are surveys of what our community members think about Circassia Pharmaceuticals and other stocks. Vote "Outperform" if you believe CIR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CIR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/26/2019 by MarketBeat.com StaffFeatured Article: How is a buy-side analyst different from a sell-side analyst?